| Dr Victor Gerard Gentile, MD | |
|
108 Bilby Rd, Suite 301, Hackettstown, NJ 07840-4174 | |
| (908) 979-0662 | |
| (908) 979-0713 |
| Full Name | Dr Victor Gerard Gentile |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 33 Years |
| Location | 108 Bilby Rd, Hackettstown, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821060187 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | MA63710 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackettstown Medical Center | Hackettstown, NJ | Hospital |
| Newton Medical Center | Newton, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocare Llc | 3678562188 | 288 |
News Archive
Futuremed Healthcare Income Fund is pleased to announce that on May 13, 2010, at its annual and special meeting of voting unitholders, unitholders overwhelmingly approved the proposed conversion of the Fund into a corporation to be called Futuremed Healthcare Products Corporation.
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.
Cancer-sensing devices built as cheaply and efficiently as wristwatches - using many of the same operating principles - could change the way clinicians detect, treat and monitor cancer in patients.
There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.
› Verified 6 days ago
| Entity Name | Advocare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770538696 PECOS PAC ID: 3678562188 Enrollment ID: O20040510001217 |
News Archive
Futuremed Healthcare Income Fund is pleased to announce that on May 13, 2010, at its annual and special meeting of voting unitholders, unitholders overwhelmingly approved the proposed conversion of the Fund into a corporation to be called Futuremed Healthcare Products Corporation.
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.
Cancer-sensing devices built as cheaply and efficiently as wristwatches - using many of the same operating principles - could change the way clinicians detect, treat and monitor cancer in patients.
There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Victor Gerard Gentile, MD 108 Bilby Rd, Suite 301, Hackettstown, NJ 07840-4174 Ph: (908) 979-0662 | Dr Victor Gerard Gentile, MD 108 Bilby Rd, Suite 301, Hackettstown, NJ 07840-4174 Ph: (908) 979-0662 |
News Archive
Futuremed Healthcare Income Fund is pleased to announce that on May 13, 2010, at its annual and special meeting of voting unitholders, unitholders overwhelmingly approved the proposed conversion of the Fund into a corporation to be called Futuremed Healthcare Products Corporation.
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
Life Technologies Corporation today announced it has received FDA 510(k) clearance for its OpTmizer CTS T-Cell Expansion Tissue Culture Medium – a reagent that is now cleared as a Class II medical device and offers cost- and time-saving advantages for transitioning studies from the research bench to clinical trials.
Cancer-sensing devices built as cheaply and efficiently as wristwatches - using many of the same operating principles - could change the way clinicians detect, treat and monitor cancer in patients.
There are two aspects to creating an effective drug: finding a chemical compound that has the desired biological effect and minimal side-effects and then delivering it to the right place in the body for it to do its job.
› Verified 6 days ago